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Recent infectionIdentiﬁcation of vulnerability in the HIV-1 envelope (Env) will aid in Env-based vaccine design. We recently
found an HIV-1 clade C Env clone (4–2.J45) ampliﬁed from a recently infected Indian patient showing
exceptional neutralization sensitivity to autologous plasma in contrast to other autologous Envs obtained at
the same time point. By constructing chimeric Envs and ﬁne mapping between sensitive and resistant Env
clones, we found that substitution of highly conserved isoleucine (I) with methionine (M) (ATA to ATG) at
position 424 in the C4 domain conferred enhanced neutralization sensitivity of Env-pseudotyped viruses to
autologous and heterologous plasma antibodies. When tested against monoclonal antibodies targeting
different sites in gp120 and gp41, Envs expressing M424 showed signiﬁcant sensitivity to anti-V3 monoclonal
antibodies and modestly to sCD4 and b12. Substitution of I424M in unrelated Envs also showed similar
neutralization phenotype, indicating that M424 in C4 region induces exposure of neutralizing epitopes
particularly in CD4 binding sites and V3 loop.ular Virology, National AIDS
, India. Fax: +91 20 27121071.
tacharya).
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The remarkable variations in the genetic diversity, glycosylation
patterns and conformational ﬂexibility of the Human Immunodeﬁciency
Virus Type 1 (HIV-1) envelope (Env), provide means for evading
antibodies that neutralize and abrogate virus infectivity (Doria-Rose
et al., 2010; Korber et al., 2001; Kwong et al., 2002; Seaman et al., 2010;
Zhang et al., 2010). Humoral immunity in particular exerts substantial
pressure on the gp120 HIV-1 envelope surface protein, leading to escape
from the autologous neutralizing antibody (NAb) response by introduc-
ing speciﬁcmutations and/or compensatory substitutions in the env gene
(Blish et al., 2008; Duenas-Decamp and Clapham, 2010; Duenas-Decamp
et al., 2008, 2009;Gray et al., 2007b, 2008;O'Rourkeet al., 2010;O'Rourke
et al., 2009; Rong et al., 2007a,b, 2009; Shen et al., 2010). While an AIDS
vaccine is urgently needed, lack of understanding of how to precisely
elicit potent and cross-reactive neutralizing antibodies (NAbs) poses a
major hurdle to vaccine development (Barouch, 2008; Fauci et al., 2008;
Walker and Burton, 2010). HIV-1 has evolved mechanisms to overcome
neutralization by autologous antibodies during the natural course of
infection wherein Env goes through substantial genetic drift due to
antibodypressure giving rise toneutralizationescape variants (Blay et al.,2006; Korber and Gnanakaran, 2009; Korber et al., 2001; Lynch et al.,
2009; Zhang et al., 2010). Thus, elucidating Env modiﬁcations that
modulate virus neutralization could illuminate howcertain changes such
as glycan positioning (Duenas-Decamp and Clapham, 2010; Duenas-
Decamp et al., 2008) and speciﬁc substitutions expose neutralizing
epitopesonEnv for better presentation towards comprehensive antibody
binding and neutralization (Li et al., 2001; Stamatatos et al., 2009; Wei
et al., 2003; Zolla-Pazner, 2004).
It was found that only a limited number of monoclonal antibodies
(MAbs) obtained from HIV-1-infected individuals have been found to
exhibit potent neutralization against a wide range of primary isolates
(Mascola and Monteﬁori, 2010;Walker and Burton, 2010; Zolla-Pazner
and Cardozo, 2010). Very recently, it was proposed that quaternary
structure-speciﬁc antibodies likely target antigenic variants speciﬁc for
similar epitopes, with neutralization breadth determined by the
prevalence of recognized variants among circulating isolates (Wu
et al., 2011). In addition, there are many well studied broadly
neutralizing human MAbs that recognize the CD4 binding site on Env
such as b12 and VRC01 (Burton et al., 1994;Wu et al., 2010; Zhou et al.,
2010), N-linked glycans on the gp120 outer domain such as 2G12
(Calarese et al., 2003; Trkola et al., 1996), and the recently described PG9
andPG16MAbs targetingV1V2 regions in gp120 (Walker et al., 2009), In
addition, three broadly neutralizing antibodies (bNAbs) viz., 2F5, 4E10
and Z13, that target themembrane-proximal external region (MPER) of
gp41 showed extensive neutralization breadth and implicate the MPER
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Muster et al., 1993; Ofek et al., 2004). MAbs and polyclonal serum
antibodies directed to the V3 loop, which are commonly found during
the course of natural infection, also are able to neutralize diverse HIV-1
strains (Bell et al., 2008; Hioe et al., 2010; Zolla-Pazner and Cardozo,
2010). Very recently, Xiang et al.(2010) demonstrated cross talk
between the V3 loop and adjacent beta strands, contributing to
stabilizing the unliganded trimer. There are a number of changes in
the HIV-1 Env that affect V3 exposure. These can result from CD4
binding aswell asmutations (Kolchinsky et al., 2001; Laakso et al., 2007;
Moore and Sodroski, 1996; Moore et al., 1993; Sullivan et al., 1998;
Walker et al., 2009; Wyatt et al., 1992; Xiang et al., 2010).
In HIV-1 clade C infections, NAbs develop during early infection to
high titer and have little or no cross neutralizing activity (Gray et al.,
2007a; Li et al., 2006). Experiments showed that antibodies elicited by
Env early in clade C infection recognize predominantly the variable loops
(Li et al., 2006; Moore et al., 2008). However, in clade C infection,
antibodies targeting the V3 loop were found to play a minimal role in
neutralization of primary viruses (Binley et al., 2004; Li et al., 2005),
possibly due to the occlusion of the V3 loop (Hartley et al., 2005;
Krachmarov et al., 2006; Pinter et al., 2004). Recent studies on subtype
C infection showed that the V1 through V4 domains were found to
modulate neutralization sensitivity of Env through occlusion of con-
served epitopes such as the coreceptor binding site (Gray et al., 2007a;
Krachmarov et al., 2005, 2006; Kwong et al., 1998; Moore et al., 2008;
Pinter et al., 2004; Sagar et al., 2006;Wyatt et al., 1995) and by shielding
of neutralization determinants (Derdeyn et al., 2004; Rademeyer et al.,
2007). Unlike V1V2, the role of V4 and V5 in neutralization resistance is
not clear (Kinsey et al., 1996; Rong et al., 2009; Wei et al., 2003).
We have recently characterized HIV-1 clade C Envs ampliﬁed from
Indian patients with recent infection, wherein we found considerable
variations in their sensitivities to autologous plasma antibodies (Ringe
et al., 2010). On further investigation,we found one Env clone (4–2.J45)
obtained from a patient (NARI-IVC4) which showed exceptional
neutralization sensitivity compared to other Envs obtained at the
same time point from the same patient. This sensitivity was noted with
both contemporaneous plasma and with autologous plasma at baseline
and from follow up visits in a longitudinal study. This prompted us to
investigate the determinants conferring such shifts in neutralization
sensitivity by making chimeric Env constructs and speciﬁc point
substitutions. We found that substitution of methionine (M) in place
of a highly conserved isoleucine (I) at position 424 in the C4 domain of
gp120, proximal to the Phe43 cavity (Kwong et al., 1998; Madani et al.,
2008; Repik and Clapham, 2008), conferred increased neutralization to
autologous and heterologous plasma antibodies obtained from clade
C infected Indian and South African donors. Further studies indicated
that I424M substitution signiﬁcantly increased sensitivity of Envs to
anti-V3 monoclonal antibodies by greater exposure of neutralizing
epitopes in V3 loop and also showed modest sensitivity to reagents
targeting CD4 binding sites (CD4bs).
Results
A clade C Env clone showed exceptional neutralization sensitivity to
autologous plasma antibodies compared to other contemporaneous Envs
from the same patient
We previously described one clade C Env clone, 4–2.J45 which, in
comparison to other contemporaneous Env clones (4–2.J41, 4–2.J42b,
4–2.J45b, 4–2.J46b and 4–2.J47b) (Ringe et al., 2010) with distinct
sequences obtained from a recently infected Indian patient, showed
greater than 80-fold increase in neutralization sensitivity when tested
against its autologous plasma (Ringe et al., 2010). These Env clones
were ampliﬁed from plasma of the patient within one year of infection
(Ringe et al., 2010). We ﬁrst sought to investigate if V1V2 played any
role in this increased autologous neutralization sensitivity, as wefound two changes in the amino acid residues in the V2 region
between the sensitive Env clone 4–2.J45 and a resistant Env clone 4–2.
J41 that has N95% similarity in protein sequence (Fig. 1). Thus, we
exchanged an Env fragment between SalI and BbvCI sites from the
resistant (4–2.J41) to the sensitive Env clone 4–2.J45 (Fig. 1) to give
rise to a chimeric Env with the 4–2.J45 backbone but with V1V2
from the resistant Env 4–2.J41. In essence, this chimeric Env [4–2.J45/
J41V1V2)] was identical to 4–2.J45 where two residues (I186V and
T195K)were substituted (found to be present in the resistant Env 4–2.
J41). However, when this chimeric 4–2.J45 (J41/V1V2) Env was tested
for its sensitivity to contemporaneous autologous plasma, it showed
sensitivity similar to the 4–2.J45 wild type (WT) (data not shown
here) indicating that the V1V2 loop did not play any role in enhanced
sensitivity of 4–2.J45 Env to autologous antibodies.Presence of a methionine at the 424 position (M424) in the C4 domain of
gp120 conferred enhanced neutralization sensitivity to autologous and
heterologous plasma antibodies
Since we found that V1V2 did not confer increased neutralization
sensitivity to autologous plasma antibodies, we next sought to map
the determinants in other regions of the Env. Using the domain
exchange strategy as described in the Materials and methods, we
exchanged gp41 between the sensitive Env (4–2.J45) and the resistant
Envs; however when tested for the neutralization sensitivity, none of
the chimeric viruses became sensitive to autologous plasma anti-
bodies, suggesting that differences in residues between 4–2.J45 and
other Envs were not basis for greater sensitivity of 4–2.J45 to
autologous neutralization. Further ﬁne mapping revealed one amino
acid change (isoleucine to methionine) in the C4 region of gp120 at
position 424 between 4–2.J45 and the rest of the contemporaneous
Envs (Fig. 1). Interestingly, we found that I424 was present in all the
resistant Envs, and isoleucine is highly conserved at the 424 position
in the HIV Los Alamos database (www.hiv.lanl.gov) across all clades in
group M HIV-1 and in SIV strains.
We next investigated whether substitution of methionine in place
of highly conserved isoleucine at position 424 would alter the overall
neutralization sensitivity to autologous plasma antibodies. By site-
directed mutagenesis, we substituted M424I in the sensitive 4–2.J45
Env and tested its sensitivity along with the 4–2.J45 WT containing
M424 to autologous plasma antibodies. As shown in Fig. 2A, with
M424I, 4–2.J45 Env became resistant to autologous plasma antibodies
collected at three different times by approximately 80-fold. Our data
suggested that indeed the presence of M424 resulted in increased
sensitivity of 4–2.J45 Env to autologous antibodies. We further tested
if I424M substitutions in four resistant Envs (obtained simultaneously
from this patient at the same time point) altered sensitivities to
autologous plasma. As shown in Fig. 2B, Env-pseudotyped viruses
containing M424 became more sensitive to autologous plasma
antibodies compared to their counterparts containing I424.
To further investigate whether M424 globally affected Env sensitiv-
ity to heterologous plasma antibodies in addition to autologous
antibodies, we tested both 4–2.J45 WT (containing M424) and 4–2.J45
(containing I424) against several HIV+ plasma collected from asymp-
tomatic patients both from India and South Africa where clade
C infection is also prevalent. As shown in Fig. 3, we observed signiﬁcant
differences (Pb0.0001) in the sensitivities between 4–2.J45 (M424) and
4–2.J45 (I424) to these heterologous plasma and serum antibodies
obtained from HIV+ Indian and South African donors, respectively.
Comparable results were obtained with unrelated HIV-1 clade C Env
11–3.J3 (Ringe et al., 2010) (P=0.0006) and clade B JRFL (P=0.008)
when tested against the same panel of HIV+ plasma specimens (data
not shown). Thus, our data showed Envs expressing M424 conferred
increased sensitivity to heterologous plasma and serum antibodies as
opposed to Envs expressing I424.
Fig. 1. Amino acid alignment between HIV-1 clade C sensitive Env (4–2.J45) and resistant Env (4–2.J41). These two Env clones were obtained from the plasma of the same patient
obtained at the same time point and found to differ signiﬁcantly in their sensitivities to autologous plasma antibodies.
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Fig. 2. Effect of I424M substitution on Env sensitivity to autologous neutralization. A. Effect of I424M substitution towards increased sensitivity of 4–2.J45 Envs to autologous plasma
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Fig. 3. Effect of Met424 and Ile424 on neutralization of Env-pseudotyped viruses by
heterologous serum and plasma antibodies obtained from asymptomatic HIV+ Indian
and South African donors. Median inhibitory dilution (ID50) of HIV+ plasma and sera
against Env-pseudotyped viruses containing Met424 and Ile424 were plotted using
GraphPad Prism software. Note that a signiﬁcant increase (Pb0.00001) in sensitivity of
Env-pseudotyped viruses occurred in the presence of Met424 in C4 domain to HIV+
plasma antibodies obtained from both Indian and South African individuals.
126 R. Ringe et al. / Virology 418 (2011) 123–132M424 signiﬁcantly enhanced Env sensitivity to anti-V3 MAbs without
altering infectivity
Since the presence of M424 conferred enhanced sensitivity to an
array of heterologous plasma and sera collected from positive donors
from distinct geographical locations, we hypothesized that this
particular substitution possibly acted upon V3 loop. Our hypothesis
wasbased on a previous observation bydifferent groups thatmajority of
HIV+plasmas predominantly target V3 loop (Carrowet al., 1991; Smith
et al., 1994; Vogel et al., 1994; Walker et al., 2010). In addition, we
previously found that the presence of the M424 residue in the 4–2.J45
Env did not signiﬁcantly alter its sensitivity toMAbs targeting theMPER
and CD4i epitopes (Ringe et al., 2010), compared to its contemporary
neutralization-resistant Env clones containing I424. We therefore
sought to examine whether I424M had affected the V3 loop which is
part of the outer domain of the Env. To test this, the sensitivities of the0
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Fig. 4. Effect of presence of Met424 on sensitivity of Env-pseudotyped viruses to anti-V3
neutralization by three anti-MAbs was tested in TZM-bl cells. Note that anti-V3 MAB 3
pseudoviruses carrying Met424 conferred enhanced sensitivity to anti-V3 MAb 3074. VC reEnv-pseudotyped viruses containing either M424 or I424 to anti-V3
MAbs 3074, 3869 and 3906weremeasured using TZM-bl target cells. As
shown in Fig. 4A, the 4–2.J45 Env containing M424 was found to be
signiﬁcantly more sensitive to anti-V3 MAbs 3074 and 3906 in contrast
to the 4–2.J45 Env containing I424. Similarly, when we substituted
methionine with isoleucine at position 424 (I424M) in related
contemporaneous Envs 4–2.J41, 4–2.J42b, 4–2.J46b and 4–2.J47b
obtained from the samepatient, a signiﬁcant increase in their sensitivity
to anti-V3 MAb 3074 (that showed best neutralization above) was
shown compared to the same Envs expressing I424 (Fig. 4B). Addition-
ally, we found that I424M substitution did not confer 4–2.J45 Env with
CXCR4 usage. These data coupled with the observation that M424 did
not alter the infectivity of Envs tested here (Fig. S1) clearly indicate that
Met424 modulated the Env conformation of the V3 loop and conferred
enhanced neutralization sensitivity to plasma antibodies without
compromising infectivity and without switching to CXCR4 usage.M424 conferred increased neutralization by plasma antibodies and anti-
V3 MAbs of heterologous clade C and clade B Envs
To further investigate whether Met424 could also enhance
neutralization sensitivity of viruses carrying heterologous HIV-1
Envs, we ﬁrst made the I424M substitution in an unrelated clade C
Env (11–3.J3) obtained from the plasma of a different Indian patient
with recent infection, reported previously (Ringe et al., 2010) as well
as three clade B Envs (JRFL, YU2 and RHPA4259.7). Env-pseudotyped
viruses containing both I424 and M424 were tested for their
sensitivities to anti-V3 MAbs as well as plasma antibodies. Since the
reactivity of 447-52D MAb was shown to be restricted by a polar
interactionwith the side chain of theR residue in theGPGRmotif found
mainly in clade B Envs but infrequently in other subtypes (Hioe et al.,
2010), 447-52D was used to test clade B Envs. As shown in Fig. 5, a
signiﬁcant increase in the sensitivity to anti-V3 MAbs of Envs
expressing M424 was found. Thus, we found that I424M signiﬁcantly
enhanced 11-3.J3 Env (unrelated clade C) (Ringe et al., 2010)
sensitivity greater than 250-fold to all three anti-V3 MAbs (3074,
3869 and 3906) tested here (Table 1 and Fig. 5A). We also tested the
effect of I424M substitution in three clade B Envs (RHPA4259.7, JRFL)
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Fig. 5. Effect of I424M substitution on neutralization sensitivities of unrelated clade C (A) and clade B (B and C) Envs. Env pseudoviruses expressing M424 showed signiﬁcant
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MAbs (3074, 3869, 3906 and 447-52D) (Table 1 and Figs. 5B and C).
Presence of M424 also showed enhanced sensitivity of heterologous
Envs to plasma antibodies, highest being 11-3.J3 (with M424)
(Table 2). Collectively, our data suggest that I424M substitution alters
the conformation of the V3 loop possibly through spatial and/or
torsional displacement of V3 base (data not shown) towards
unmasking of discontinuous epitopes to anti-V3 MAb in unliganded
state (Xiang et al., 2010).
Presence of M424 in the C4 domain affects gp120 interaction with CD4
but not with CCR5
Since Met424 is very close to the 17b antibody binding site and
inﬂuences the conformation of V3 as evidenced by imparting increasedTable 1
Neutralization sensitivities of Envs to different anti-V3 MAbs.
Neutralization sensitivity to anti-V3 MAbs
IC50 (μg/ml)
Envelope Clade Ile424 Met424
4.2J45 C N50 (3074, 3869, 3906) b0.390625 (3074); N50 (3869);
3.125 (3906)
11-3.J3 C 50 (3074, 3869, 3906) b0.390625 (3074; 3869; 3906)
RHPA4259.7 B N50 (3074, 3869, 3906,
447-52D)
N50 (3074; 3906); 20 (3869); 26
(447-52D)
YU2 B N50 (3074, 3869, 3906,
447-52D)
N50 (3074; 3906); 8 (3869); 1.1
(447-52D)
JRFL B N50 (3074, 3869, 3906,
447-52D)
N50 (3074; 3906); 15 (3869);
1.56 (447-52D)
IC50 values indicate the concentration of anti-V3 MAb resulting in 50% reduction in
infectivity of Env-pseudotyped viruses in the TZM-bl cells. The anti-V3 MAbs used in
this study are given in parenthesis next to their respective IC50 values.sensitivity to anti-V3 antibodies, we investigated if this residue also
inﬂuences coreceptor binding. To test this, we incubated TZM-bl cells
with different molar concentrations of CCR5 ligand TAK-779 for 1 h
following which Env-pseudotyped viruses expressing M424 and I424
were added and incubated further for two days. As shown in Fig. 6A, no
signiﬁcant differences in inhibition of infectivity by TAK-779 were
observed between viruses expressing either Met424 or Ile424, although,
only4–2.J41Envcontaining Ile424 showedrelativelygreater sensitivity to
TAK-779 than 4–2.J41 withMet424 (~14-folds). These data demonstrate
that although the M424I substitution affected V3 conformation, it
generally showed b4-fold impact on Env interaction with CCR5.
The 424 position in Env also resides in the vicinity of the structurally
conserved Phe43 cavity on gp120 (Kwong et al., 1998; Madani et al.,
2008; Repik and Clapham, 2008). To test whether I424M substitution
could also alter gp120–CD4 interaction, a clone of HeLa cells expressing
low cell surface CD4 and high CCR5 (RC49 clone) (Platt et al., 1998) was
infected with Env-pseudotyped viruses expressing M424 and I424, andTable 2
Effect of I424M substitution on Env sensitivity to PG9, PG16, VRC01 and pooled plasma.
Values represent 50% inhibitory concentration (µg/ml) of MAbs tested. For plasma
specimens, values represent reciprocal dilution at which 50% neutralization was
observed.
Envelope PG9 PG16 VRC01 b12 Pooled plasma
4–2.J45 (I424) 0.018 0.16 0.42 N10 67
4–2.J45 (M424) 0.125 6 0.6 N10 7046
11–3.J3 (I424) 0.44 0.47 0.8 N10 443
11–3.J3 (M424) 0.49 0.92 0.51 N10 2938
JRFL (I424) N10 N10 0.1 0.1 97
JRFL (M424) N10 N10 0.05 0.05 132
YU2 (I424) N10 0.15 0.06 3.55 134
YU2 (M424) 1.26 0.05 0.05 0.11 324
RHPA4259.7 (I424) N10 0.12 b0.03 0.23 108
RHPA4259.7 (M424) N10 0.21 b0.03 0.06 280
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signiﬁcant difference in TAK-779 mediated inhibition was found due to the presence of M424. However, the presence of M424 showed modest increase in Env sensitivity to sCD4
both in related Envs (obtained from same patient at the same time point) (B) and unrelated clade B and C Envs (C) indicating that M424 imparted conformational shifts towards
better binding with CD4. VC refers to virus control.
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described earlier (Ringe et al., 2010). Env-pseudotyped viruses expres-
singM424 showed increases in infection of HeLa RC49 cells (Fig. S2). In
addition,M424 also showed amodest increase inEnv sensitivity to sCD4
both in contemporaneous (related) Envs and in unrelated clade B and C
Envs (Figs. 6B and C). Our data provided evidence that alteration at
position 424 in gp120 affects its interactionwith CD4but notwithCCR5.
I424M substitution did not impact on quaternary epitopes in gp120 but
showed modest shift in sensitivity to CD4bs antibodies
We next wanted to test if I424M substitution altered β20 sheet
towards inﬂuencing the conformation of the outer domain of gp120
besides V3 loop. Thus, we examined whether I424M can alter the
neutralization sensitivity of Envs to the MAbs that recognizes the
CD4bs and to the conformational quaternary neutralizing epitopes
(QNE). As shown in Table 2, we did not ﬁnd any signiﬁcant shifts in
the neutralization sensitivity of Envs to PG9 and PG16 with I424M
substitution, except YU2, where we found N8 and 3-fold increase in
sensitivity (IC50) of Env expressing M424 to PG9 and PG16
respectively. Interestingly, 4–2.J45 Env expressing M424 showed
relative resistance to PG9 and PG16 over 4–2.J45 expressing I424
(Table 2), wherein we found comparable sensitivities of other Envs to
PG9 and PG16 except YU2, which showed approximately 8 and 3 fold
increase in neutralization sensitivity to PG9 and PG16 MAbs
respectively (Table 2). The indistinctness in PG9/PG16 sensitivities
of 4–2.J45 and YU2 Envs expressing M424 was possibly due to some
compensatory and conformational changes elsewhere within Env.
Overall, we did not ﬁnd any association between I424M substitution
and neutralization sensitivity.
We next assessed if presence of M424 confers Env with increased
sensitivity to MAbs targeting CDbs. Since we previously found that theclade C Envswere resistant to b12 (Ringe et al., 2010),we tested effect of
I424M substitution of Env susceptibility to MAbs to CD4bs i.e., b12 and
VRC01. As shown in Table 2, I424M substitution in JRFL, RHPA4259.7
and YU2 Envs conferred increase in b12 sensitivity by 2, 3.8 and 32.27
folds respectively. Thus, although overall the shift in b12 sensitivity due
to I424M was modest (P=0.14), the 2 and approximately 4-fold
increase in b12 sensitivity of JRFL (Tier 2) and RHPA4259.7 (Tier 2)
expressing M424 was noted. However, when tested against recently
discovered CD4bs MAb, VRC01 MAb, both Envs expressing M424 and
I424 showed comparable sensitivity to VRC01; thus no signiﬁcant
difference (P=0.2) in the VRC01 sensitivity (Table 2). Our data suggest
that I424M while appearing to modulate CD4bs epitopes modestly did
not show deﬁnitive effect on quaternary epitopes targeted by PG9 and
PG16 MAbs. Additionally, I424M was not found to have any signiﬁcant
difference in the sensitivity of Envs to 4E10MAb targetingMPER in gp41
(Ringe et al., 2010) even at higher concentrations up to 10 μg/ml (data
not shown), negating any signiﬁcant exposure of neutralizing epitopes
in MPER due to I424M substitution.
Discussion
Characterization of the NAb targets on the HIV-1 Env early in
infection will allow a better understanding of the epitopes vulnerable
for virus neutralization and will have implications for rational Env-
based vaccine design. In the present study, we sought to understand
the basis of the exceptional sensitivity of a clade C Env to autologous
plasma compared to other Envs obtained at the same time point from
a recently infected Indian patient. Using Env chimeras constructed
with sensitive and resistant Envs with closely related protein
sequences followed by ﬁne mapping we found a single substitution
of methionine in place of the relatively conserved isoleucine at
position 424 in the C4 region of Env conferred increased virus
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when we examined the HIV database (www.hiv.lanl.gov), we found
that methionine is completely absent in viruses at the 424 position in
the HIV-1M, N and O groups. It is possible that the 4–2.J45 Env variant
was selected in vivo to acquire this rare residue early in the infection
although this change was not found in other Env clones obtained
either from the same time point or from the baseline (collected six
month prior) as well as follow up plasma specimens (collected six
months after) of the same individual (Ringe et al., 2010). Although we
do not rule out the possibility of introduction of this unusual I424M
substitution due to PCR error (albeit we used high ﬁdelity proof
reading polymerase during Env ampliﬁcation and except 4–2.J45 Env,
other Env clones ampliﬁed from the same patient at the same time
contained the conserved I424), nonetheless, M424 was found to
confer comparable infectivity to those containing I424, suggesting
substitution of methionine at this position was not associated with
defective production of infectious virions.
Interestingly, with introduction of M424 replacing the exceptionally
conserved I424 (www.hiv.lanl.gov), all the neutralization-resistant
pseudotyped viruses containing contemporaneous Envs from the same
patient became signiﬁcantly sensitive to autologous plasma antibodies,
suggesting that M424 indeed induced conformational shifts in Env
towards greater exposure of neutralizing epitopes that are otherwise
obscured. Notably, the fact that Env variants substituted with I424M in
the C4 region of gp120 showed increased sensitivity to plasma antibodies
from heterologous sources indicated that despite other differences
between Env sequences, I424M substitution alone is capable of
modulating Env conformation resulting greater exposure of neutralizing
epitopes. Presence of such circulating envelope in plasma is perplexing
and it is expected that such envelopes would perish quickly. We did not
ﬁnd such Env variants (M424) obtained at later time points in this
particular patient support this view and hence we assume that 4–2.J45
might have certain advantage for example resistance to cell-mediated
immune response or higher infectivity topersist for a small periodof time
(Bunnik et al., 2008; Rong et al., 2009). Since M424 conferred enhanced
neutralization sensitivity to autologous plasma antibodies collected at
different time points from this particular (IVC4) patient, we further
sought to understand if epitopes that are targeted by autologous plasma
antibodies in this patient constitute major targets of neutralizing
antibodies during early infection. Thus, when we compared the
vulnerabilities between Env containingM424 and I424 towards effective
neutralization by several heterologous HIV+ plasma and serum
antibodies essentially collected at early infection from Indian and South
African donors, we found that Env-pseudotyped viruses containing
Met424 indistinct genetic backgrounds (both in cladeBandcladeCEnvs)
became increasingly sensitive to heterologous plasma antibodies. The
modest increase in neutralization sensitivity of unrelated Envs compared
to 4–2.J45 due to I424M substitution to pooled plasma as shown in
Table 2 was probably due to presence of residues elsewhere in 4–2.J45
Env that provided 4–2.J45with conformation for enhanced susceptibility
to plasma antibodies. Nonetheless, increase in the sensitivity of JRFL
(subtype B) which is a Tier 2 virus (Mascola et al., 2005) after I424M
substitution to plasma and serum antibodies obtained from clade C
individualswas remarkable. Overall, our study indicated that substitution
of highly conserved isoleucine with methionine at 424 position in C4
domain in gp120 resulted in exposure of neutralizing epitopes.
Did Met424 induce conformational shifts in Env towards enhanced
sensitivity of Env-pseudotyped viruses to plasma antibodies by actingon
particular sites on Env? Nakamura et al.(1993) previously reported
antibodies that targets neutralizing epitopes in C4 domain and
prevented CD4 binding with gp120; they speciﬁcally showed that
mutation of residues at position 423 and 429 in C4 region in gp120
governs inhibition by a population of CD4 blocking antibodies. Based on
our observation that I424Msubstitution showedenhanced susceptibility
of Envs tested in the current study toplasmaantibodies, it is possible that
presence of M424 affects population of antibodies targeting C4 region ingp120. Also, we found that M424 is located in close proximity to the
Phe43 cavity, a site shown to be vulnerable for neutralizing antibodies
and agents that interferes with gp120–CD4 interaction and has been
implicated as a potentially attractive target for blocking virus entry
(Kwong et al., 1998, 2002; Madani et al., 2008; Repik and Clapham,
2008). Indeed, we found that I424M substitution impacted on exposure
of discontinuous CD4bs epitopes that was indicated by increased
sensitivity of Envs to sCD4 and moderate enhancement of clade B Envs
to b12 MAb. However, VRC01, another CD4bs antibody showed
comparable Env sensitivity and did not show any signiﬁcant shifts in
Env sensitivity due to presence ofM424. Thiswaspossibly due to the fact
that I424M do not impact on conformationalmasking of VRC01 epitope.
Interestingly, the modest increase in b12 sensitivity also correlated with
the increased sensitivity of Envs to sCD4 and modest increase in the
infectivity of HeLaRC49 cells (expressing low surface CD4)due to I424M
substitution which suggest structural alteration at CD4bs with I424M
substitution resulting in exposure of neutralizing epitopes important for
gp120-CD4 interaction. The position 424 in C4 region in gp120 is also in
close proximity to the epitope recognized by 17b, a MAb that targets
CD4i region (data not shown here). However, we recently showed that
the 4–2.J45 Envwas completely resistant to 17b (Ringe et al., 2010) thus
eliminating any effect on alteration of CD4i region due to presence of
M424. In addition, we did not ﬁnd signiﬁcant inhibition of Env-
pseudoviruses to CCR5 antagonist TAK-779 due to I424M substitution.
Recently, Xiang et al. (Xianget al., 2010)demonstrated that I424S change
in YU2 Env has no effect on CCR5 binding. This indicates I424M
substitution did not affect the structural integrity of coreceptor binding
site. Nonetheless, 4–2.J45 Env expressing M424 did show increased
sensitivity to sCD4 compared to contemporaneous Env clones at a
concentration greater than 6.66 μg/ml (Ringe et al., 2010). In the present
study, we further assessed whether Met424 indeed confers greater
sensitivity of other Envs substituted withM424 in place of I424 to sCD4.
As expected, with I424M substitution, pseudotyped viruses containing
contemporaneous Envs and Envs obtained from unrelated patients
showed enhanced sensitivity to sCD4. In particular 4–2.J41, 4–2.J46b and
4–2.J47b Envs showed remarkable shift towards enhanced sensitivity to
sCD4. In addition, these Env-pseudotyped viruses also showed modest
utilization of HeLa cells expressing lowbut highCCR5on their surface for
efﬁcient entry. Collectively, these observations suggest that M424
modulated conformation of gp120 improving gp120-CD4 interaction.
To further narrow down the region in the Env outer domain that
conferred signiﬁcant sensitivity to plasma antibodies, we tested Env-
pseudoviruses containing M424 and I424 to three well characterized
anti-V3 MAbs that were previously shown to be cross-reactive (Jiang
et al., 2010). To our surprise, we found that Env-pseudotyped viruses
containingM424 showed≥100-fold increased sensitivity to the anti-V3
MAbs (notably with MAb 3074) in contrast to Env-pseudotyped viruses
containing I424 and was closely comparable to that observed with
plasma antibodies. This was probably due to increased accessibility of
critical neutralizing epitopes in V3, resulting in better antibody binding,
and virus neutralization. The I424M substitution although was found to
modulate the V3 loop conformation it does not appear to inﬂuence
quaternary epitopes in gp120 as we found no association of I424M
substitution with shift in the Env sensitivity to PG9 and PG16MAbs that
targets the quaternary epitopes. Also, the I424M substitution was not
found to have signiﬁcant difference in the sensitivity to MAbs targeting
MPER such as 4E10 (Ringe et al., 2010) even at higher concentrations
(data not shown). Thus, we conclude that I424M substitutions
predominantly modulated V3 loop conformation in addition to
exposition of discontinuous neutralizing epitopes on CD4bs on Env
which predominantly accounted for greater neutralization by autolo-
gous and heterologous plasma antibodies. The anti-V3 antibody titer
produced in vivomay not be potent enough (possibly due to inefﬁcient
exposure of neutralizing epitopes in primary virus) to bind and
neutralize efﬁciently the virus post CD4 engagement which causes
exposure of V3 loop for coreceptor binding (Huang et al., 2005; Xiang et
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loop. It is possible that increased exposureofneutralizingepitopesdue to
presence of M424 would be able to efﬁciently present these epitopes
(which otherwise remains occluded in primary viruses) to B cells and
elicit potent antibodies, which might interfere virus entry in the small
window period post CD4 bound state.
We sought to understand how alteration in gp120 conformation due
to speciﬁc mutation such as I424M in C4 domain exposes the
neutralizing epitopes for effective antibody recognition. It was reported
earlier (Bhattacharya et al., 2003; Clapham et al., 1989; Hart et al., 1991;
Moore et al., 1990, 1992; Sattentau et al., 1993) that pre-treatment of
HIV-1, HIV-2 andSIVwith sCD4 confers increasedexposure ofV2 andV3
loops, signiﬁcant reduction in infection of target cells, and increased
neutralization by anti-V3 antibodies. In addition, laboratory adapted
viruses such asHIV-1 IIIb, LAV-2ROD and SIVmac251were demonstrated
to have exposed V3 loop prior to sCD4 binding (Sattentau et al., 1993).
Thesedata suggest that Envs that are less CD4-dependent for productive
entry tends to shift V3 loop away from the Env core thereby exposing
sites vulnerable for neutralization. In our study, we found that Envs
expressing M424 showed modest increase in their sensitivity to sCD4,
supporting earlier ﬁndings that suggest an association between
increased Env sensitivity to sCD4 and enhanced neutralization by anti-
V3 antibodies. Although I424Mshowedmodulation inV3 loop, however
it did not appear to modulate quaternary epitopes in V1/V2 and V3
regions that are targeted by PG9 and PG16MAbs. Interestingly, 4–2.J45
Env in presence of M424 showed relative resistance to PG9 and PG16,
possibly due to presence in compensatory residues elsewhere in this
particular Env. It has been shown that many primary envelopes with
closely similar V3 sequence were found to be resistant to anti-V3
antibodies (Hioe et al., 2010) suggesting that V3 loop is well poised to
evade from such antibodies in the trimeric Env structure while
maintaining the primary function of coreceptor binding. This suggests
that apart from changes within V3, other proximal elements of gp120
that interactswithV3 loop for example stemof V1V2 and bridging sheet
modulate the binding of anti V3 antibodies to V3 loop structure. Such
alteration likely resulted in unmasking of neutralizing discontinuous
epitopes by shifting V3 loop away from Env core that were universally
targeted by plasma antibodies tested here. In summary, our present
study indicated that changes inβ20 strand inC4domain of gp120due to
I424M substitution resulted in alteration in Env conformation towards
exposure of discontinuous neutralizing epitopes in V3 and CD4bs that
form the basis for enhanced virus neutralization by plasma antibodies.
Materials and methods
Patient materials, antibodies and inhibitors
Plasmaand serumsamples from individuals infectedwithHIV-1were
obtained from National AIDS Research Institute (NARI) clinics, Pune,
India, following ethical approval by the institutional review board (IRB).
Serum and plasma that were tested for neutralization assays were
obtained from blood samples donated by the HIV+ individuals during
their routine testing at their ﬁrst visit for acquisition of HIV-1 at the NARI
clinics andwere later conﬁrmed forp24 antibodypositivity by serological
testing. Plasma samples of patients with recent infection (estimated
through detuned ELISA) from which HIV-1 gp160 clones were obtained
have been described recently (Ringe et al., 2010). Twenty HIV+ plasma
samples from the South African donors infected with HIV clade C were
generously provided by Prof Lynn Morris, National Institute of
Communicable Diseases, Johannesburg, South Africa. Plasma and serum
sampleswereheat inactivatedat 55 °C for 1 hbeforeuse inneutralization
assays. The MAbs speciﬁc for the V3 loop, 3074, 3869 and 3906, and for
parvovirus (MAb 1418) used in this study were described previously
(Gorny et al., 2009;Hioe et al., 2010). VRC01MAbwaskindly providedby
Dr John Mascola, VRC, NIH, USA. PG9 and PG16 MAbs obtained from
International AIDS Vaccine Initiative (IAVI) and were described before(Walker et al., 2009). CCR5 antagonist, TAK-779, TZM-bl cells, 447-52D
(MAb toV3) andanti-p24hybridoma183-H12-5C (Chesebroet al., 1992)
were obtained from the NIH AIDS Research Reagents and Reference
Program. Soluble CD4 (sCD4) was purchased from Progenics, Inc. and
was providedbyDrDavidMonteﬁori, DukeUniversity, Durham,NC,USA.
Construction of Env chimera
To ﬁnd speciﬁc regions in Env modulating neutralization sensitivity,
fragmentswere swappedbetween resistant (4–2.J41) and sensitive (4–2.
J45) Env clones. Primers were designed to speciﬁcally amplify the region
in Env inserted andalso theprimers that ampliﬁedentire backboneof the
plasmid except the insert. These two PCR products generated amplicons
having at least 15basepair homologous sequences at 5′and3′endsof the
DNA fragments. The insert and backbone fragmentsmixed in a 1:2molar
ratio with a cocktail containing pox DNA polymerase provided in Dry
Down PCR cloning kit (Clontech Inc.) according to manufacturer's
instructions. This In-Fusion enzyme produces single stranded overhangs
by its exonuclease activity which is then annealed due to 15 base pair
homology.
Site-directed mutagenesis
Speciﬁc primers were designed to introduce desired residue both in
insert and in backboneDNAby PCR. Ampliconswere puriﬁed and further
digested with DpnI to remove any residual template plasmid DNA.
Ligations were carried out using dry-down PCR kit (Clontech Inc.) as
described above.
Neutralization assays
Neutralization assays were carried out in TZM-bl cells using Env-
pseudotyped viruses as described previously (Ringe et al., 2010). Brieﬂy,
200 TCID50 of Env-pseudotyped viruses were incubated with various
dilutions and concentrations of heat-inactivated patient's plasma/sera
andMAbs in a total volume of 150 μl (for plasma samples) or 100 μl (for
MAbs) for 1 h at 37 °C in 96-well tissue culture plates (Corning, Inc.).
Freshly trypsinized TZM-bl cells (1×104/well) were subsequently
added to each well with 25 μg/ml DEAE Dextran and further incubated
for additional 2 days at 37 °C in a CO2 incubator. One set of control wells
received TZM-bl cells plus Env-pseudotyped virus (virus control) and
another set received cells only (cell control). The reduction in infectivity
was calculated by measuring the relative light units (RLU) of the
infected TZM-bl cells in a luminometer (Perkin Elmer, Inc).
Infectivity assays in HeLa cells
Single round infectivity assays in HeLa cells were done as described
before (Ringe et al., 2010). Brieﬂy, Env-pseudotyped viruses were
normalized against their TZM-bl infectivity titers and subsequently
200TCID50 (relative to TZM-bl cells) were mixed with 1×104/well of
HeLa (RC49) cells in a 96-well tissue culture plate without DEAE
Dextran. The entire mixture was then incubated further for 2 days in a
CO2 incubator at 37 °C. Virus infectivitywasmeasured by immunostain-
ing intracellular p24 as described previously (Peters et al., 2004).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.07.015.
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